BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Diabetes. Apr 15, 2026; 17(4): 116772
Published online Apr 15, 2026. doi: 10.4239/wjd.v17.i4.116772
Table 2 Univariate analysis of risk factors for rapid estimated glomerular filtration rate decline, n (%)
Risk factors
Rapid decline (n = 89)
Non-rapid decline (n = 213)
χ2 value
P value
Age
≥ 60 years58 (65.2)96 (45.1)15.32< 0.001
< 60 years31 (34.8)117 (54.9)
Diabetes duration
≥ 10 years54 (60.7)82 (38.5)18.76< 0.001
< 10 years35 (39.3)131 (61.5)
HbA1c control
≥ 8.0%52 (58.4)56 (26.3)32.45< 0.001
< 8.0%37 (41.6)157 (73.7)
Baseline eGFR
< 60 mL/minute/1.73 m264 (71.9)72 (33.8)41.28< 0.001
≥ 60 mL/minute/1.73 m225 (28.1)141 (66.2)
UACR
≥ 300 mg/g58 (65.2)48 (22.5)52.36< 0.001
< 300 mg/g31 (34.8)165 (77.5)
Systolic blood pressure
≥ 140 mmHg58 (65.2)84 (39.4)22.15< 0.001
< 140 mmHg31 (34.8)129 (60.6)
Diastolic blood pressure
≥ 90 mmHg38 (42.7)62 (29.1)8.470.004
< 90 mmHg51 (57.3)151 (70.9)
Hyperuricemia
Yes56 (62.9)68 (31.9)26.83< 0.001
No33 (37.1)145 (68.1)
Anemia
Yes62 (69.7)68 (31.9)31.54< 0.001
No27 (30.3)145 (68.1)
Hypoalbuminemia
Yes34 (38.2)48 (22.5)12.65< 0.001
No55 (61.8)165 (77.5)
History of hypertension
Yes72 (80.9)142 (66.7)9.820.002
No17 (19.1)71 (33.3)
History of coronary heart disease
Yes28 (31.5)42 (19.7)7.310.007
No61 (68.5)171 (80.3)
RAAS inhibitor use
Non-use42 (47.2)60 (28.2)11.730.001
Use47 (52.8)153 (71.8)
SGLT-2 inhibitor use
Non-use61 (68.5)110 (51.6)8.950.003
Use28 (31.5)103 (48.4)


Write to the Help Desk